Technology
Improves Quality of Life
Strong Track Record of Safety & Effectiveness
Easy to Use Device
Breaking the Cycle of Excess Mucus, Inflammation, and Infection
ARINA·1 is a novel, at-home nebulized therapy that restores overall lung health by clearing mucus, reducing inflammation, and inhibiting bacterial growth. Our initial focus is on individuals with prevention of BOS progression in lung transplant, non-CF bronchiectasis (NCFBE), and nontuberculous mycobacterial lung disease (NTM-LD).
Breaking the Vicious Cycle of Mucus in the Lungs
Excess mucus and pathological inflammation damage the airway, leaving it more susceptible to infection.
Thick Mucus Accumulates in Airways
Inflammation Damages Airway
Increased Risk of Bacterial Infection
Over 25 patient-years of clinical safety and efficacy data supported
by clean chronic toxicology data.
How ARINA·1 Breaks the Cycle
Improves
Mucociliary Clearance
-
Thins mucus viscosity
-
Improves ciliary function
-
8x more effective than hypertonic saline for clearing mucus
Decreases
Inflammation
-
Decreases inflammation comparably to potent steroids without harmful side effects
-
No evidence of neutropenia or increased risk of infection, even with long-term use
Inhibits
Bacterial Growth
-
Direct anti-bacterial effect
-
Broad-spectrum activity without promoting bacterial resistance
-
Inhibits Gram positive (e.g., MRSA), Gram negative (e.g., Pseudomonas aeruginosa), and NTM bacteria (e.g., M. abscessus, MAC)
-
Target Indications
In our target diseases, thick mucus often accumulates in the lungs and cannot be effectively cleared out of the airways, which leads to mucus plugging and difficulty breathing.
